Pomegranate to Reduce Maternal and Fetal Oxidative Stress and Improve Outcome in Pregnancies Complicated With Preterm Premature Rupture of the Membranes
1 other identifier
interventional
100
1 country
1
Brief Summary
In this study the investigators sought to determine the effects of Pomegranate (Natural pomegranate polyphenol (P. granatum L) extract) :
- 1.On the maternal and fetal oxidative stress and inflammation associated with PPROM.
- 2.On the time interval from PPROM to delivery and on fetal Ph and apger score.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Apr 2012
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2012
CompletedFirst Submitted
Initial submission to the registry
April 16, 2012
CompletedFirst Posted
Study publicly available on registry
April 24, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2015
CompletedApril 24, 2012
April 1, 2012
3 years
April 16, 2012
April 22, 2012
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Oxidative Stress
Serum lipid peroxidation 1. Serum lipids peroxidation 2. Lipid peroxide formation 3. Paraoxonase activity measurements
Measurments will be first taken at the day of admission (for the mother) and will be assessed immediatly after delivery (mother and newborn)
Secondary Outcomes (1)
Obstetrical outcomes
Measurments will be first taken at the day of admission (for the mother) and will be assessed immediatly after delivery (mother and newborn)
Study Arms (2)
Pomegranate pills
ACTIVE COMPARATORtreatment with pomgranate pills to women suffering preterm premature rupture of membranes
placebo pills
PLACEBO COMPARATORtreatment with placebo to women with preterm premature rupture of membranes
Interventions
Treatment arm will receive The POMx pomegranate 1,000 mg capsule a day for maximum of two weeks or until they deliver if occurs before The POMx pomegranate 1,000 mg capsule contains at least 800 mg natural polyphenol using a pomegranate polyphenol standard and is comparable to mg/8 oz juice.(attached is confirmation Similarity of Pomegranate Juice and POMx Polyphenols)
The placebo group will receive placebo pills , for maximum of two weeks or until they deliver if occurs before The palecbo capsule contains gelatin and lactose. The capsuls are manufactured by the hospital pharmacy.All the components are medically approved fot use during pregnancy
Eligibility Criteria
You may qualify if:
- pregnancy
- singleton pregnancy
- preterm premature rupture of membranes
- gestational age \> 24Wks
You may not qualify if:
- gestational age \> 24wks
- fetal anomalies
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Rambam Health Care Campus
Haifa, Israel
MeSH Terms
Conditions
Study Officials
- PRINCIPAL INVESTIGATOR
Ido Solt, M.D
Rambam Health Care Campus
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- M.D
Study Record Dates
First Submitted
April 16, 2012
First Posted
April 24, 2012
Study Start
April 1, 2012
Primary Completion
April 1, 2015
Study Completion
May 1, 2015
Last Updated
April 24, 2012
Record last verified: 2012-04